Arbutus Biopharma (ABUS) Upgraded at ValuEngine

Arbutus Biopharma (NASDAQ:ABUS) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Monday.

ABUS has been the topic of several other reports. Zacks Investment Research cut shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Thursday, January 18th. BidaskClub upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, February 10th. Wedbush cut shares of Arbutus Biopharma from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $9.00 to $6.00 in a report on Monday, March 19th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Arbutus Biopharma in a research report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. Arbutus Biopharma has an average rating of “Hold” and an average price target of $12.38.

How to Become a New Pot Stock Millionaire

Arbutus Biopharma stock traded up $0.15 during midday trading on Monday, hitting $5.15. 213,618 shares of the stock were exchanged, compared to its average volume of 183,744. Arbutus Biopharma has a 52-week low of $2.95 and a 52-week high of $8.25. The stock has a market cap of $275.35, a PE ratio of -2.88 and a beta of 1.06. The company has a debt-to-equity ratio of 0.09, a quick ratio of 8.85 and a current ratio of 8.85.

Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.51). Arbutus Biopharma had a negative return on equity of 55.28% and a negative net margin of 796.23%. The firm had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $0.70 million. analysts predict that Arbutus Biopharma will post -1.7 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. bought a new stake in Arbutus Biopharma in the third quarter worth about $1,393,000. RTW Investments LP raised its position in Arbutus Biopharma by 1.1% in the third quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock worth $32,651,000 after acquiring an additional 56,457 shares during the period. Victory Capital Management Inc. raised its position in Arbutus Biopharma by 16.6% in the fourth quarter. Victory Capital Management Inc. now owns 150,720 shares of the biopharmaceutical company’s stock worth $761,000 after acquiring an additional 21,460 shares during the period. Hudson Bay Capital Management LP raised its position in Arbutus Biopharma by 239.0% in the fourth quarter. Hudson Bay Capital Management LP now owns 400,000 shares of the biopharmaceutical company’s stock worth $2,020,000 after acquiring an additional 282,000 shares during the period. Finally, OxFORD Asset Management LLP raised its position in Arbutus Biopharma by 49.2% in the third quarter. OxFORD Asset Management LLP now owns 124,273 shares of the biopharmaceutical company’s stock worth $778,000 after acquiring an additional 40,963 shares during the period. 62.12% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was published by WKRB News and is owned by of WKRB News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.wkrb13.com/2018/04/03/arbutus-biopharma-abus-upgraded-at-valuengine.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply